InnoCare Pharma Management
Management criteria checks 3/4
InnoCare Pharma's CEO is Jasmine Cui, appointed in Aug 2016, has a tenure of 9.58 years. total yearly compensation is CN¥19.50M, comprised of 25.3% salary and 74.7% bonuses, including company stock and options. directly owns 5.95% of the company’s shares, worth HK$1.35B. The average tenure of the management team and the board of directors is 3.4 years and 6 years respectively.
Key information
Jasmine Cui
Chief executive officer
CN¥19.5m
Total compensation
| CEO salary percentage | 25.27% |
| CEO tenure | 9.6yrs |
| CEO ownership | 6.0% |
| Management average tenure | 3.4yrs |
| Board average tenure | 6yrs |
Recent management updates
Recent updates
Pinning Down InnoCare Pharma Limited's (HKG:9969) P/S Is Difficult Right Now
Jan 26
An Intrinsic Calculation For InnoCare Pharma Limited (HKG:9969) Suggests It's 45% Undervalued
Jan 06Earnings Update: InnoCare Pharma Limited (HKG:9969) Just Reported Its Interim Results And Analysts Are Updating Their Forecasts
Nov 16Some InnoCare Pharma Limited (HKG:9969) Shareholders Look For Exit As Shares Take 26% Pounding
Oct 14InnoCare Pharma Limited (HKG:9969) Shares Could Be 33% Below Their Intrinsic Value Estimate
Sep 19Subdued Growth No Barrier To InnoCare Pharma Limited (HKG:9969) With Shares Advancing 33%
Jul 24Despite Lacking Profits InnoCare Pharma (HKG:9969) Seems To Be On Top Of Its Debt
Jul 15What InnoCare Pharma Limited's (HKG:9969) 26% Share Price Gain Is Not Telling You
Apr 22
Advancing Orelabrutinib And Autoimmune Therapies Will Open New Market Opportunities
Orelabrutinib's market position and expansion are set to boost revenue, supported by ongoing clinical advancements and strategic approvals.Is There An Opportunity With InnoCare Pharma Limited's (HKG:9969) 49% Undervaluation?
Mar 17InnoCare Pharma Limited (HKG:9969) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected
Feb 18Pinning Down InnoCare Pharma Limited's (HKG:9969) P/S Is Difficult Right Now
Dec 18Is InnoCare Pharma (HKG:9969) A Risky Investment?
Oct 21Subdued Growth No Barrier To InnoCare Pharma Limited (HKG:9969) With Shares Advancing 29%
Sep 13Analyst Estimates: Here's What Brokers Think Of InnoCare Pharma Limited (HKG:9969) After Its Half-Yearly Report
Aug 22Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?
Jun 21Some Analysts Just Cut Their InnoCare Pharma Limited (HKG:9969) Estimates
Apr 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -CN¥230m |
| Jun 30 2025 | n/a | n/a | -CN¥209m |
| Mar 31 2025 | n/a | n/a | -CN¥280m |
| Dec 31 2024 | CN¥20m | CN¥5m | -CN¥441m |
| Sep 30 2024 | n/a | n/a | -CN¥376m |
| Jun 30 2024 | n/a | n/a | -CN¥471m |
| Mar 31 2024 | n/a | n/a | -CN¥761m |
| Dec 31 2023 | CN¥23m | CN¥5m | -CN¥631m |
| Sep 30 2023 | n/a | n/a | -CN¥584m |
| Jun 30 2023 | n/a | n/a | -CN¥867m |
| Mar 31 2023 | n/a | n/a | -CN¥781m |
| Dec 31 2022 | CN¥24m | CN¥4m | -CN¥887m |
| Sep 30 2022 | n/a | n/a | -CN¥987m |
| Jun 30 2022 | n/a | n/a | -CN¥296m |
| Mar 31 2022 | n/a | n/a | -CN¥78m |
| Dec 31 2021 | CN¥29m | CN¥3m | -CN¥65m |
| Sep 30 2021 | n/a | n/a | CN¥60m |
| Jun 30 2021 | n/a | n/a | -CN¥266m |
| Mar 31 2021 | n/a | n/a | -CN¥329m |
| Dec 31 2020 | CN¥120m | CN¥1m | -CN¥391m |
| Sep 30 2020 | n/a | n/a | -CN¥2b |
| Jun 30 2020 | n/a | n/a | -CN¥2b |
| Mar 31 2020 | n/a | n/a | -CN¥2b |
| Dec 31 2019 | CN¥17m | CN¥3m | -CN¥2b |
Compensation vs Market: Jasmine's total compensation ($USD2.83M) is above average for companies of similar size in the Hong Kong market ($USD676.45K).
Compensation vs Earnings: Jasmine's compensation has been consistent with company performance over the past year.
CEO
Jasmine Cui (62 yo)
Dr. Jisong Cui, Ph.D. also known as Jasmine, has been Co-Founder InnoCare Pharma, Ltd. and serves as Chief Executive Officer of InnoCare Pharma, Ltd. since August 18, 2016 and its Chairwoman since Septembe...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.6yrs | CN¥19.50m | 5.95% HK$ 1.3b | |
| Senior VP of Clinical Development & Medical Research and Executive Director | no data | CN¥4.33m | 8.25% HK$ 1.8b | |
| Chief Financial Officer | 2.3yrs | no data | no data | |
| Chief Operating Officer | 4.7yrs | no data | no data | |
| Accounting Supervisor | no data | no data | no data | |
| Chief Technology Officer | 6.4yrs | no data | 0.0074% HK$ 1.6m | |
| General Counsel | 4.5yrs | no data | no data | |
| VP & Head of Biology | 4.5yrs | no data | no data | |
| Chief Commercial Officer | 2.2yrs | no data | no data | |
| Senior Vice President of Biology & Biologics | 1.2yrs | no data | no data | |
| C.M.O | less than a year | no data | no data | |
| C.B.O | less than a year | no data | no data |
Experienced Management: 9969's management team is considered experienced (3.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 10.3yrs | CN¥19.50m | 5.95% HK$ 1.3b | |
| Senior VP of Clinical Development & Medical Research and Executive Director | 10.3yrs | CN¥4.33m | 8.25% HK$ 1.8b | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Non-Executive Director & President of Scientific Advisory Board | 10.3yrs | no data | 0.23% HK$ 50.8m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Non-Executive Director | 5yrs | no data | no data | |
| Independent Non-Executive Director | 6yrs | CN¥360.00k | no data | |
| Independent Non-Executive Director | 2.4yrs | CN¥360.00k | no data | |
| Independent Non-Executive Director | 1.2yrs | no data | no data |
Experienced Board: 9969's board of directors are considered experienced (6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/05 16:43 |
| End of Day Share Price | 2026/03/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
InnoCare Pharma Limited is covered by 21 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Peng Zou | China International Capital Corporation Limited |
| Jin Zhang | China International Capital Corporation Limited |